~," The effects of aspirin and meclofenamic acid on the diphasic responses produced by prostacyclin in isolated canine basilar arteries were compared. Meclofenamate enhanced the relaxant action of prostacyclin in low concentrations (10-SM to 104M) and also significantly inhibited the contractions caused by the highest concentration (10-SM) of this prostaglandin. Aspirin had no such effects. The results indicate that some drugs classified as prostaglandin synthetase inhibitors can directly enhance the vasodilator action of prostacyclin on cerebral arteries, and suggest that this enhancement could be of value in the clinical applications of prostacyclin.
R
ECENT reports indicate that prostacyclin (PGI2) may function as a physiological cerebral vasodilator, s,4 and will inhibit platelet aggregation. 15 On the other hand, many prostaglandins (PG's), such as PGF~ and platelet thromboxane A2, cause vasoconstriction 2~ and may be associated with cerebral vasospasm as well as thrombotic or embolic stroke? 4 Prostaglandin synthesis inhibitors (PSI's), such as aspirin, are frequently used in the treatment of threatened stroke because of their antiplatelet aggregating properties, but high doses of aspirin may cause cerebral thrombosis by inhibiting prostacyclin production in vascular endothelium? TM Likewise, in selecting therapeutic agents for the treatment of cerebral vasospasm after subarachnoid hemorrhage, it would seem advantageous to use agents that would not interfere with the protective vasodilating prostacyclin system. Recent animal studies in our laboratory have demonstrated the efficacy of PSI's in vitro 5"6 and in vivo 2s in treating cerebral arteriospasm. To clarify whether or not PSI's would also inhibit the dilator action of prostacyclin, the following study on isolated basilar arteries was undertaken.
Materials and Methods
Mongrel dogs of both sexes were anesthetized with intravenous sodium pentobarbital (30 mg/kg) and rapidly exsanguinated via the femoral artery. After brain removal, the basilar artery was dissected and placed in a dish of Krebs-Ringer buffer solution at 37~ A 4-mm segment was taken from the midportion of the vessel and mounted on rigid parallel prongs with the aid of an operating microscope. The bath chamber used was similar to that described by others 2' 18 except that ours contained 25 ml of buffer. Meticulous handling of the vessel and a time interval of less than 20 minutes from sacrifice to mounting were found to be crucial in obtaining a good preparation. Damage to the arterial smooth muscle was minimized by using the arachnoid mater to handle the segment. The chamber was filled with 25 ml of KrebsRinger buffer solution (mM concentration): NaC1 120, KCI 4.5, CaC12 2.5, MgSO4 1.0, NaHCO, 27.0, KH2PO( 1.0, NaEDTA 0.01, and glucose 10.0. A gas mixture of 95% O~ and 5% CO~ was continuously bubbled through the bath chamber and buffer reservoir to provide oxygenation, mixing, and calcium Prostacyclin and prostaglandin synthetase inhibitors stability. Temperature was maintained at 37~ • 0.05 ~ . The vessel was initially washed frequently, and no agents were tested for at least 2 hours. Early in this period, resting tension was set at 1.0 gm for 11/2 hours, and then raised to 3 gm, where it remained for the duration of the experiment. Isometric tension was recorded using a Grass polygraph and a Statham strain gauge transducer held by a fine-positioning device to accurately adjust resting tension.* Test agents and inhibitors were added in 0.025-to 0.25-ml amounts. Serotonin creatinine sulfate (5-HT) was made fresh daily with deionized water, and prostacyclin was prepared just before use by dissolving it in 0.1 M Tris buffer at pH 9.1 and was kept on ice throughout the experiment. Aspirin and meclofenamate were solubilized in water by the incremental addition of 0.1 N NaOH. The final pH of these solutions was approximately 7.5 and 9.6, respectively. The addition of the vehicle alone to the bath chamber did not affect vessel contractility. Several log doseresponse curves for 5-HT were obtained in each preparation before the addition of inhibitors, and were repeated periodically between tests. After each trial the vessel was washed 10 times with 60 ml of buffer, and after 2 to 3 minutes of washing the vessel consistently returned to its initial resting tension. A 20-minute delay was allowed between trials to assure full recovery of the vessel. Aspirin was added to the chamber 20 minutes before the addition of 5-HT, because this incubation period was used in a related study; 2x however, although we varied this period from 5 to 45 minutes, it did not alter our findings. Meclofenamate was added 5 to 10 minutes before the agonists.
In earlier experiments it was determined that 5-HTinduced contractions were not significantly affected by the previous addition of meclofenamate (1 • 10-'M) or aspirin (1 X 10-'M or 1 X 10-SM). For this reason, these concentrations of the inhibitors were used to determine whether these inhibitors would subsequently modify known responses caused by prostacyclin.' Further, it was found that a 1 • 10-eM concentration of 5-HT produced a maximum response that did not significantly fade over the time required to obtain log dose-responses to prostacyclin. When higher concentrations of 5-HT (1 • 10-SM) were used, it was found that a much less contracted state was induced (see also Allen, et aL2). For these reasons an initial contractile state was induced with 1 • 104M of 5-HT in all preparations. Preliminary observations indicated that meclofenamate in 10-SM concentrations *Grass Model 7 polygraph manufactured by Grass Instrument Co., Quincy, Massachusetts. Statham strain gauge transducer, 11388, G1-1.5-300, manufactured by Statham Laboratories, Oxnard, California. Fine-positioning device, FTA 1011, manufactured by Hewlett Packard Co., Palo Alto, California. yielded equivocal effects on the phenomena studied, and that in 10-SM concentrations it significantly inhibited contractions induced by 5-HT? For these reasons a 10-4M concentration was selected for this study. When 10-'M of aspirin yielded negative results, a higher dose was tested on the assumption that it might simply be less potent than meclofenamate. Also, the diphasic effect of prostacyclin reported herein is characteristic of this compound,' and therefore the contractions it produced in high concentrations did not depend on the presence of 5-HT. Serotonin was used in this study to produce initial contractions in order that the relaxant properties of prostacyclin could be studied more quantitatively. The Student's t-test was used to determine the level of significance? ~ It is unknown whether the concentrations of aspirin and meclofenamate used in this study would be present in blood vessels in vivo. However, this is possible because the concentrations of such drugs in different tissues may vary at least eightyfold, and alter independent of blood values. TM Moreover, the recommended therapeutic blood level for aspirin (MW = 180) in rheumatic fever is 30 mg%? 5 This is greater than a 1 • 10 SM concentration, which is the highest used in this study (Table 1) . Such concentrations are commonly used in pharmacological studies with other inhibitors of isolated vascular smooth muscle (such as papaverine), and are often higher than that required for contractile agonists? ~
Results
Meclofenamate in 10'M concentrations enhanced the relaxation induced by the lower doses of prostacyclin on the contracted basilar artery ( Fig. 1 and Table 1 ). This enhancement was statistically significant at 10-SM of prostacyclin (p < 0.05), where the relaxation was double that induced before meclofenamate. The enhancement was questionable statistically at 10-1M to 10-6M of prostacyclin (p < 0.1) as peak relaxation approached maximum (Fig. 1) . However, an analysis by,the sum of probabilities TM indicates that this trend very closely approached significance at p < 0.05, and therefore it is likely that meclofenamate materially increased the relaxation caused by all three lower concentrations of prostacyclin. Although meclofenamate enhanced the relaxation caused by low concentrations of prostacyclin, it significantly inhibited the contractions induced by the highest dose (15 < 0.005), as best seen in Fig. 1 . Prior to meclofenamate administration, the highest dose of prostacyclin produced a contracted state that was greater than that caused by 5-HT alone (14.5 compared with 13.6 gm), whereas afterward it was only 61% as great. In contrast, the contractions induced by optimum concentrations of 5-HT (10-6M) were not altered (Table 1) . Hence, meclofenamate inhibited the contractile properties of prostacyclin and, paradoxically, enhanced the relaxation induced by this prostaglandin.
In contrast to meclofenamate, aspirin at both concentrations studied neither enhanced the relaxation nor inhibited the contractions observed with the log dose-responses induced by prostacyclin ( Table 1 ). The responses produced by prostacyclin after 10-'M concentrations of aspirin were virtually similar to those obtained before. However, in 10-SM concentrations aspirin appeared to actually reduce the magnitude of the relaxation produced by the 107M and 10-SM concentrations of prostacyclin, although this change was not significant statistically. It is evident, therefore, that the pharmacodynamic action of aspirin was completely different from that of meclofenamate.
Discussion
Prostacyclin is the main prostaglandin synthesized by the endothelium of vessels; 12' 15 cerebral arteries synthesize this 8,1~ and other prostaglandins? ~ This synthesis appears essential for the integrity of normal circulation. Prostacyclin is a potent vasodilator and prevents the aggregation of, and even deaggregates, platelets? ,9,15 It is the physiological antagonist of thromboxane A=, which is synthesized by platelets? ,~* Some investigators have postulated that cerebral vasospasm 8 and other vascular diseases" may be due to an imbalance in the synthesis of different prostaglandins. The half-life of prostacyclin in blood is longer than that of thromboxane, and it is considered a circulating hormone, the function of which is to restrict the unwarranted spread of thrombi.'."
Since arachidonic acid is a precursor of both thromboxane A= and prostacyclin, there is presently much interest in the use of PSI's,rwhich selectively inhibit synthesis of thromboxane, to combat thrombotic stroke." In this regard, the beneficial action of aspirin is related more to low dosage rather than to enzyme specificity. TM Another therapeutic approach would be to supplement the naturally occurring prostacyclin. For this purpose, prostacyclin is being tested as a treatment for peripheral vascular disease, for thrombotic stroke, for use in coronary bypass surgery, and as an inhibitor of platelet activity during ex~racor-poreal circulation." Prostacyclin may eventually prove efficacious in the management of certain neurosurgical problems, such as carotid endarterectomy, thrombotic stroke, and cerebral vasospasm. It ]90
Prostacyelin and prostaglandin synthetase inhibitors is, therefore, important to characterize the action of this prostaglandin on cerebral vessels and determine whether PSI's might pharmacologically alter the responses induced. Recent findings showed that in threshold concentrations prostacyclin relaxes isolated cerebral arteries, 8,4 and this appears to be the only prostaglandin that has this characteristic.' Other prostaglandins and arachidonic acid in low concentrations produce constriction of the isolated basilar artery. 5,6 Aspirin and indomethacin reportedly enhance the constriction caused by prostaglandins F2~ and E2 on dog cerebral arteries, and theoretically would be questionable therapy for cerebral vasospasm?' However, meclofenamate inhibits contractions induced by arachidonic acid and prostaglandin F~. 5,8 Since both aspirin and meclofenamate reduced slightly (but not enough to be statistically significant) the resting tone of some of the preparations, it is apparent from the literature that a major difference in the actions of these drugs is on the contractions produced by prostaglandins. This'is also evident with high concentrations of prostacyclin, in which aspirin failed to block this megadose response whereas meclofenamate did ( Table 1) . Whether either of these drugs would interfere with the physiological vasodilatatory action of prostacyclin is unknown.
The present study clearly shows, therefore, that meclofenamic acid enhanced the relaxant effects of prostacyclin on the basilar arteries of dogs and reduced the constriction obtained with high concentrations. Aspirin had no such effect, and tended to facilitate the constrictor action. Such distinct pharmacological differences among these PSI's may be clinically important, as it suggests that patients under the influence of meclofenamate might have an exaggerated vasodepressor response ,to prostacyclin, while any constrictor action associated with large doses, or overdosage, would be reduced. Since the constrictor action of prostacyclin was also significantly reduced by meclofenamate, it is possible that the enhanced relaxation was due to an unmasking of an unknown and unrecordable simultaneous constrictor action of prostacyclin that occurs with the lower doses. A similar mechanism seems to account for the effect of polyphoretin phosphate on the vascular actions of other prostaglandins in the intact dog, 24 and may be operating here. In this regard, it is possible that the different effects of meclofenamate and aspirin are due to actions independent of prostaglandin synthesis. Meclofenamate inhibits such synthesis by cerebral arteries, ~~ and blocks the synthesis of these lipids by the heart in response to ischemia, and aspirin clearly inhibits platelet cyclooxygenase, ~' 8 but this class of drugs also inhibits the influx of calcium in vitro ~7 and it is possible that only meclofenamate exerted such an effect on the cerebral arteries. Meclofenamate does not inhibit phosphodiesterase. 1 Aspirin inhibits many enzyme systems, 2" but these apparently played no role in the phenomena studied. Regardless of the mechanism, the present study emphasizes further that the effects of compounds pharmacologically classified as PSI's are complex, 7a3 and that some, but not all, will significantly change the pharmacodynamic actions of prostacyclin on cerebral arteries. It is possible that in the future some PSI's may be used clinically to inhibit platelet function while enhancing directly the vasodilator action of prostacyclin. Meclofenamic acid could be such a drug.
